Milestone Pharmaceuticals Inc.·4

Feb 4, 5:50 PM ET

Oliveto Joseph 4

4 · Milestone Pharmaceuticals Inc. · Filed Feb 4, 2026

Research Summary

AI-generated summary of this filing

Updated

Milestone (MIST) CEO Joseph Oliveto Receives Option and RSU Awards

What Happened
Joseph Oliveto, President, CEO and a director of Milestone Pharmaceuticals (MIST), received two equity awards on February 2, 2026: a grant of 679,000 option-based derivative shares and a grant of 453,000 restricted stock units (RSUs). Both awards were reported at $0.00 per share (typical for compensation grants) and are derivative/contingent awards rather than open‑market purchases or sales.

Key Details

  • Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely).
  • Awards: 679,000 shares (derivative option award) and 453,000 restricted stock units (RSUs). Reported price: $0.00.
  • Vesting for the option award (F1): 1/4 vests on Feb 2, 2027, then 1/36 of the remaining shares vest each month thereafter, subject to continued service.
  • RSU details (F2, F3): Each RSU converts to one common share; 1/4 of RSUs vest on each of Feb 2, 2027, 2028, 2029 and 2030, subject to continued service.
  • Shares owned after the transaction are not specified in this filing. No exercise, sale, tax withholding, or 10b5‑1 plan is indicated in the reported items.

Context
These are standard compensation grants to a company executive. The option award is not an exercise (no shares were purchased or sold); the RSUs are a contingent right to receive common shares if vesting conditions are met. Grants like these are common in executive compensation and do not by themselves indicate trading sentiment.

Insider Transaction Report

Form 4
Period: 2026-02-02
Oliveto Joseph
DirectorPresident and CEO
Transactions
  • Award

    Employee Stock Option (right to buy)

    [F1]
    2026-02-02+679,000679,000 total
    Exercise: $1.97Exp: 2036-02-02Common Shares (679,000 underlying)
  • Award

    Restricted Stock Unit

    [F2][F3]
    2026-02-02+453,000453,000 total
    Common Shares (453,000 underlying)
Footnotes (3)
  • [F1]One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
  • [F2]Each restricted stock unit represents a contingent right to receive one common share.
  • [F3]One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.
Signature
/s/ Joseph Oliveto|2026-02-04

Documents

1 file
  • 4
    form4-02042026_050201.xmlPrimary